GlucoTrack (GCTK)
NASDAQ:GCTK
Want to see GCTK full AI Analyst Report?
GCTK Stock Chart & Stats
$1.93
-$0.03(-1.53%)
At close: 4:00 PM EST
$1.93
-$0.03(-1.53%)
Day’s Range― - ―
52-Week Range$0.29 - $14.14
Previous Close$0.14
Volume19.82K
Average Volume (3M)2.54M
Market Cap
$2.07M
Enterprise Value-$3.69M
Total Cash (Recent Filing)$3.93M
Total Debt (Recent Filing)$26.00K
Price to Earnings (P/E)―
Beta2.98
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.31
Shares Outstanding6,259,279
10 Day Avg. Volume100,775
30 Day Avg. Volume2,541,249
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.23
Price to Sales (P/S)0.00
P/FCF Ratio-0.23
Enterprise Value/Market Cap-1.78
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit167.56
Enterprise Value/Ebitda0.22
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Validated Preclinical DataA peer‑reviewed long‑duration ovine study showing a 6.8% MARD, 240‑day implants and no device‑related adverse events materially reduces technical and safety risk. This durable evidence strengthens regulator, clinician and partner confidence and supports progression to human trials and commercial credibility.
IDE Submission To FDAFiling an IDE is a structural milestone moving the program from preclinical validation toward regulated clinical evaluation in the U.S. Clearance would enable pivotal data collection, advance regulatory strategy and move the company closer to a commercial pathway that can generate recurring device and software revenue.
IP, Manufacturing & Go‑to‑Market PrepA portfolio of U.S. patents combined with dual contract manufacturing and a defined reimbursement approach creates durable competitive moats. Experienced management and operational planning increase the probability of executing clinical trials, securing payor coverage and scaling commercialization if clinical and regulatory milestones are met.
Bears Say
Pre‑commercial Financial ProfileThe company remains pre‑commercial with negligible revenue and persistent multi‑million dollar operating cash burn. Without near‑term product revenue, GlucoTrack must rely on external financing, which increases execution risk and can constrain R&D and trial pacing if capital access tightens over the coming months.
Nasdaq Delisting RiskMultiple Nasdaq deficiency notices create structural governance and liquidity risk. Potential delisting would materially reduce access to capital markets, impair secondary trading liquidity and raise business continuity concerns, which could force hurried financing or strategic changes that harm long‑term execution.
Reliance On Dilutive FinancingRepeated debt‑for‑equity transactions lower near‑term debt but demonstrate dependence on equity dilution to manage obligations. This pattern signals limited access to non‑dilutive capital, risks cumulative shareholder dilution, and could complicate future fundraising or strategic partnerships essential to fund clinical development.
GlucoTrack News
GCTK FAQ
What was GlucoTrack’s price range in the past 12 months?
GlucoTrack lowest stock price was $0.29 and its highest was $14.14 in the past 12 months.
What is GlucoTrack’s market cap?
GlucoTrack’s market cap is $2.07M.
When is GlucoTrack’s upcoming earnings report date?
GlucoTrack’s upcoming earnings report date is Aug 13, 2026 which is in 47 days.
How were GlucoTrack’s earnings last quarter?
GlucoTrack released its earnings results on May 14, 2026. The company reported -$2.646 earnings per share for the quarter, missing the consensus estimate of N/A by -$2.646.
Is GlucoTrack overvalued?
According to Wall Street analysts GlucoTrack’s price is currently Overvalued.
Does GlucoTrack pay dividends?
GlucoTrack does not currently pay dividends.
What is GlucoTrack’s EPS estimate?
GlucoTrack’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GlucoTrack have?
GlucoTrack has 6,259,279 shares outstanding.
What happened to GlucoTrack’s price movement after its last earnings report?
GlucoTrack reported an EPS of -$2.646 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.84%.
Which hedge fund is a major shareholder of GlucoTrack?
Currently, no hedge funds are holding shares in GCTK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GlucoTrack
Based in Or Yehuda, Israel, GlucoTrack, Inc. is a medical technology company focused on innovating, developing, and bringing to market non-invasive glucose monitoring systems. Their primary offering, the GlucoTrack device, enables individuals with diabetes or pre-diabetes to painlessly check their blood glucose levels. This technology is available to customers both in Israel and across the globe. The company, founded in 2001, operated under the name Integrity Applications, Inc. until it officially rebranded to GlucoTrack, Inc. in November 2021.
Technical Analysis
Ownership Overview
0.18% Insiders
0.18% Mutual Funds
0.80% Other Institutional Investors
98.85% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---